Keros Therapeutics, Inc.

NASDAQ:KROS

Biotechnology

Healthcare
$12.00 +1.20%

+$0.13 today

Market cap
$235.49M
Beta
0.96
P/E (TTM)
-4.6
EPS (TTM)
-$2.29
52W Low $9.69High $22.55

Volume 0.55M

Average 0.36M

KROS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Keros Therapeutics, Inc.NASDAQ: KROS

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $6.2M fell 30.1% year over year, behind the -27.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 15.1% from the prior quarter. Over 3 fiscal years it compounded at +15.4% a year.

Context

  • Stock-based compensation amounted to 11.8% of revenue in FY2025, down 970.6 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -30.1% toward the trailing-twelve-month pace of -27.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.2M-15.1% QoQ
Last fiscal yearDec 2025
$28.7M-17.7% YoY
LTMMar 2026
$26.03M-27.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.1%——
1 year-17.7%——
3-year CAGR+15.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
28.7M USD
Year-over-year change
-17.7%
4-year CAGR
+25.1%

Stock-Based Compensation vs competitors

How KROS compares with its peers on the latest reported figures

  • KROS's LTM Mar 2026 stock-based compensation of $26.03M is the 2nd largest of the 10 companies compared; the peer median is $12.84M.
  • Its year-over-year change of -27.0% is the 9th highest of 10, against a peer median of +21.4%.
  • Stock-based compensation amounts to 78.5% of revenue for KROS, versus a peer median of 22.6%.
KROS Competitors Peer median
Stock-Based Compensation for KROS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RGNXREGENXBIO Inc.LTM Mar 2026$34.64M -7.4%-5.4%39.4%
KROSKeros Therapeutics, Inc.LTM Mar 2026$26.03M -27.0%+15.4%78.5%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$23.96M +203.5%+10.1%—
ABSIAbsci CorporationLTM Mar 2026$13.53M -11.4%+13.5%737.0%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$13.21M -40.1%——
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$12.84M +21.4%+0.9%4.3%
VSTMVerastem, Inc.LTM Mar 2026$9.66M +26.4%+15.9%19.5%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$9.12M +17.3%-21.7%25.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$6.73M +88.8%+25.6%—
NAGENiagen Bioscience IncLTM Mar 2026$6.71M +79.0%+1.9%5.1%
Peer median (excluding KROS) $12.84M+21.4%+6.0%22.6%

Competitors are the stored peer set for KROS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(58.74M)(104.68M)(152.99M)(187.35M)87.01M
Depreciation & Amortization378K674K815K1.23M1.51M
Deferred Income Tax46K0000
Stock-Based Compensation11.72M18.68M28.76M34.87M28.7M
Change in Working Capital(16.07M)14.31M(2.65M)(11.44M)(12.11M)
Accounts Receivables(18M)18M(143K)(2.6M)(825K)
Inventory1.04M0(4.51M)00
Accounts Payables1.49M(408K)1.61M(249K)(3M)
Other Working Capital(597K)(3.28M)384K(8.59M)(8.29M)
Other Non-Cash Items520K953K1.56M1.82M2.4M
Operating Cash Flow(62.15M)(70.06M)(124.51M)(160.87M)107.51M
Capital Expenditures(1.02M)(1.24M)(2.46M)(1.93M)(1.55M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(1.02M)(1.24M)(2.46M)(1.93M)(1.55M)
Debt Repayment00000
Common Stock Issued28.17M119.58M175.83M380.13M(3.47M)
Common Stock Repurchased0000(375M)
Dividends Paid00000
Other Financing Activities379K731K3.13M11.69M0
Financing Cash Flow28.55M120.31M178.96M391.82M(378.47M)
Effect of Forex Changes00000
Net Change in Cash(34.62M)49.01M51.98M229.02M(272.52M)
Free Cash Flow(63.17M)(71.3M)(126.97M)(162.8M)105.95M

Keros Therapeutics, Inc.

NASDAQ:KROS

Intrinsic Alpha fair value

Locked

Current Price

$12.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.